LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Metagenomics Analysis Tool Reduces False Discovery Rates

By LabMedica International staff writers
Posted on 30 Mar 2015
Image: Many molecular biology studies begin with purified DNA and RNA extracted from complex environments such as the human gut (Photo courtesy of Los Alamos [US] National Laboratory).
Image: Many molecular biology studies begin with purified DNA and RNA extracted from complex environments such as the human gut (Photo courtesy of Los Alamos [US] National Laboratory).
Genomic researchers recently described a novel new tool for analyzing the complex data generated during DNA screens of mixed populations of organisms such as the human gut microbiome.

DNA screening of entire communities of organisms has been termed metagenomics. Such screening generates an enormous data set of short sequences, or "reads," which must be evaluated in order to yield meaningful information. While existing microbial community profiling methods have attempted to rapidly classify the millions of reads output from modern DNA sequencing platforms, the combination of incomplete databases, similarity among otherwise divergent genomes, errors and biases in sequencing technologies, and the large volumes of sequencing data required for metagenome sequencing has led to unacceptably high false discovery rates (FDR).

To correct these problems, investigators at the Los Alamos National Laboratory (New Mexico, USA) developed a new method for analysis of DNA sequencing data. The new tool, described in the March 12, 2015, online edition of the journal Nucleic Acids Research, is called Genomic Origins through Taxonomic CHAllenge or GOTTCHA, which makes use of a database of reference genomes that have been preprocessed to retain only unique segments of the genomes at any level of taxonomy.

GOTTCHA analyzes the distribution and depth of coverage of only the unique fraction of each reference genome—the unique genome—to identify the true community composition and accurate relative abundance of members of the community. GOTTCHA uses empirically-derived coverage limits, supported by machine-learning approaches, to set the limits of detection. The result is a scalable, all-purpose, metagenomic community profiler with superior classification and statistical performance over all currently available tools.

"We have developed a new tool in this rapidly expanding and evolving field of what is called metagenomics," said senior author Dr. Patrick Chain, metagenomics team leader at the Los Alamos National Laboratory. "It uses nucleic acid data and looks for sections that map uniquely to a preconstructed database."

"Metagenomics is the study of entire microbial communities using genomics, such as when you sequence the DNA of a whole community of organisms at once," said Dr. Chain. "The result is an enormous data set of short sequences, or reads, that you need to sort through to try to understand which organisms are actually present, and what they may be doing. Here at Los Alamos, we specialize in incredibly large data sets; we know how to handle them whether it is for physics, ocean, or climate modeling, or for complex biological insights."

The GOTTCHA software, associated databases, and training datasets are accessible to biotech researchers online (please see Related Links below).

Related Links:
Los Alamos [US] National Laboratory
GOTTCHA


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Gold Member
Hematology Analyzer
Medonic M32B

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more